Swiss Software Stock News

SGS (SWX:SGSN) has just released full year 2025 results, reporting sales of CHF 6,945 million and net income of CHF 668 million, figures that suggest operational improvement compared with the prior year. See our latest analysis for SGS. SGS shares last closed at CHF94.2, and the stock has had a 90 day share price return of 4.88%, while the 1 year total shareholder return sits at 1.90%, with the 3 year total shareholder return at 20.65% and 5 year total shareholder return at 5.94%. This points...

Straumann Holding (SWX:STMN) announced an increase to its annual dividend alongside the release of its latest full year financial results. The new dividend level reflects the board's current capital allocation decision following the recent earnings announcement. This update adds a fresh data point for investors tracking the company's income profile and cash returns. Straumann Holding's latest dividend move comes after a challenging share price period, with the stock at CHF91.7 and showing a...

Sika (SWX:SIKA) is back in focus after recent share price moves that left the stock about 4.7% lower year to date, despite a roughly 5.8% gain over the past month. See our latest analysis for Sika. The recent 5.8% 30 day share price return contrasts with a year to date share price decline of about 4.7%. At the same time, the 1 year total shareholder return of roughly 31.8% and 5 year total shareholder return of about 32.7% signal fading longer term momentum. If this mixed picture has you...

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...

Alcon (SWX:ALC) is back in focus after the U.S. launch of its TOTAL30 Multifocal for Astigmatism contact lenses, a product aimed at presbyopic patients with astigmatism who have limited soft lens options. See our latest analysis for Alcon. The TOTAL30 Multifocal for Astigmatism launch comes as Alcon’s share price sits at CHF63.78, with a 7 day share price return of 6.1% but a 1 year total shareholder return decline of 20.6%, suggesting recent momentum contrasts with weaker longer term...

Belimo Holding (SWX:BEAN) reported full-year 2025 earnings with sales of CHF 1,120.81 million, net income of CHF 181.63 million, and basic EPS of CHF 14.77 from continuing operations. See our latest analysis for BELIMO Holding. The earnings release and cautious 2026 outlook have coincided with some pressure on the shares, with a 1-day share price return of a 10% decline and a 7-day share price return of a 6.3% decline. At the same time, the 1-year total shareholder return of 36.7% and 5-year...

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...

Why Novartis Stock Is On Investors’ Radar Today Novartis (SWX:NOVN) has drawn fresh attention after recent performance data showed a 9.9% return over the past month and 23% over the past 3 months, prompting investors to reassess its current valuation profile. See our latest analysis for Novartis. Beyond the recent jump, Novartis’ 16.55% year to date share price return and 33.45% one year total shareholder return suggest momentum has been building around its CHF126.46 share price and ongoing...

Nestlé (SWX:NESN) has set out a company wide shakeup, moving to sell its remaining ice cream assets, explore exits from vitamins and waters, and concentrate on coffee, petcare, nutrition, and food and snacks. See our latest analysis for Nestlé. These portfolio moves and the recent earnings update have come alongside a 10.55% 1 month share price return to CHF80.91. The 1 year total shareholder return of a 1.51% decline shows momentum has only recently started to improve after weaker multi year...

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...

CPH Group (SWX:CPHN) has reported fresh numbers for FY 2025, with second half revenue of CHF158.1 million and basic EPS of CHF1.04, alongside trailing 12 month revenue of CHF334.1 million and EPS of CHF3.90 that reflect a very large 402.6% earnings jump over the last year and a net margin that has increased to 7% from 1%. The company has reported revenue rising from CHF146.4 million and EPS of CHF2.23 in the second half of 2024 to CHF175.9 million and EPS of CHF2.85 in the first half of...

Sunrise Communications (SWX:SUNN) has wrapped up FY 2025 with Q4 revenue of CHF 788.8 million and a net income loss of CHF 50.1 million, while the trailing twelve months show revenue of CHF 2.98 billion alongside a loss of CHF 112.2 million. The company has seen quarterly revenue move in a tight band between CHF 722.1 million and CHF 788.8 million from Q1 to Q4 2025, with basic EPS ranging from a loss of CHF 0.022 in Q1 to a loss of CHF 0.075 in Q3. This keeps the spotlight squarely on when...

If you are wondering whether Novartis shares still offer value at current levels, this article walks through what the numbers say about the price you are paying versus what you are getting. The stock last closed at $126.48, with returns of 2.2% over 7 days, 10.7% over 30 days, 16.6% year to date, 35.5% over 1 year, 85.7% over 3 years and 104.7% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Novartis have...

ams-OSRAM (SWX:AMS) has attracted fresh attention after its Open System Protocol for automotive lighting progressed toward ISO standard status, positioning the company more firmly within next generation vehicle electronics architectures. See our latest analysis for ams-OSRAM. That progress toward an ISO standard comes shortly after ams-OSRAM reported 2025 results that showed sales of €3,323m with a net loss of €130m, alongside guidance for first quarter 2026 revenues between €710m and €810m...

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

Earnings call and dividend decision draw focus to ALSO Holding (SWX:ALSN) ALSO Holding (SWX:ALSN) is back on investor radars after its 2025 earnings call on 17 February 2026 coincided with the announcement of an annual dividend of CHF 5.30 per share. See our latest analysis for ALSO Holding. The earnings call and dividend announcement came against a weak backdrop, with a 1 day share price return of 31.17% decline and a 1 year total shareholder return of 46.43% decline suggesting momentum has...

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.

If you are wondering whether ABB is still fairly priced after a strong run, this article will walk through what the current share price might be implying about value. ABB's share price closed at CHF 69.80, with returns of 1.7% over 7 days, 13.3% over 30 days, 14.0% year to date, 34.5% over 1 year, 139.7% over 3 years and 215.6% over 5 years. This raises the question of what is already reflected in the price. Recent news around ABB has focused on its position as a global industrial technology...

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.